Major gram-negative bacterial pathogens Flashcards
-Morphology, growth requirements and classification of key Gram-negative bacteria. Neisseria infections and pathogenicity. -Haemophilus infections and pathogenicity. -Yersinia and Pseudomonas infections and pathogenicity, epidemiology and spread. - Control of Gram-negative bacterial infections including antibiotic treatment, prophylaxis and use of vaccines, as appropriate.
Gram negative cell surface antigens
H-antigen (flagellum)
K-antigen (capsule)
Peptidoglycan
O antigen (outer membrane LPS)
The gram-negative cell envelope
Outer membrane:
-LPS is intimately attached to the outer membrane
-capsule is loosely attached
-both are antigens confer some resistance to immune system
-lipoproteins link OM to peptidoglycan layer - gives cell rigidity
Inner membrane:
-contains many transport proteins and components of bacterial respiratory chain
-these enable bug to get energy from growth substrate
LPS O-antigens
Deters complement c567 - Membrane Attack Complex precusors
-membrane pore in target cell
Capsule evades antibody binding
Meningitis and gonorrhoea gram-negative genera
Neisseria
Meningitis, pneumonia gram-negative genera
Haemophilus influenzae
plague – millions of deaths in medieval times
Gram-negative genera
Yersinia pestis
Burn infections and lung infections of CF patients
Gram-negative genera
Pseudomonas aeruginosa
GI tract gram-negative genera
Salmonella spp.- gastroenteritis
Shigella spp.- gastroenteritis
Vibrio cholera- cholera – GI lecture
Helicobacter pylori- stomach ulcers- GI lecture
Camplylobacter jejuni- food poisioning- GI lecture
Whooping cough gram-negative genera
Bordetella
Legionnaires disease gram-negative genera
Legionella
‘The Clap’ syphilis gram-negative genera
Treponema pallidum
Neisseria spp.
Gram-negative diplococci
N. meningitidis - meningococcus
N. gonorrhoeae - gonococcus
Both fastidious - growth (heated blood [chocolate]) + CO2
N. meningitidis - meningococcus
Meningitis/ meningococcal septicaemia
Infection of CSF and meninges
Commensal carriage in pharynx/nasopharynx
Capsular, serotyping based on polysaccharides
N. gonorrhoeae - gonococcus
Gonorrhoea
STI, genital and oral infection
Neonatal transfer- eye infections
Lipooligosaccharide capsule often sialylated> STI lecture
The meninges
Pia mater, arachnoid mater, dura mater
Symptoms of meningitis
Floppy child/ difficulty supporting own weight Fever, vomiting, diarrhoea Confusion and drowsiness Severe headache Stiff neck Dislike of bright light Body stiffness/ jerky movements
N. meningitidis
10 - 25% nasopharynx commensal carriage rate
During disease episodes, carriage rate may rise to 90%
5 Serogroups:
-dependent on polysaccharide capsular antigen
-serogroups A,B,C,Y,W135- account for almost all cases worldwide
N. meningitidis UK
Serogroup B- 90% confirmed cases
(since introduction of Group C vaccine, now replaced with ACYW vaccine from 2015)
Serogroups A, C,and W135 comprise others
N. meningitidis pathogenesis: spread
either directly to subarachnoid space or through nasopharyngeal mucosa to enter the bloodstream
N. meningitidis pathogenesis
Possess IgA protease for serum resistance
In most first infection leads to ab production without development of clinical disease
Bactericidal antibody against capsule is most important protective factor
-meningitis still relatively rare in UK
N. meningitidis epidemiology
Occurs worldwide and is WHO and NHS notifiable
Outbreaks occur in winter months
Approx. 2000 cases and 80 deaths per year in UK (4%)
2/3 of cases occur in first 5 years of life
Peak prevalence is in first year of life, second peak 16-23 years
Frequent outbreaks among
young adult population (military, university)
Worldwide picture: meningitis
Highest occurrence of meningitis is in a region of sub-saharan Africa- ‘meningitis belt’
During outbreaks can cause infection of up to 10% of population – mainly Serogroup A
Diagnosis and treatment of meningitis
Speed is the key: 6-24hr onset
CSF
-many PMNLs, presence of bacteria- diplococci
Blood culture
-sub-culture on chocolate agar
-sugar fermentation tests – maltose & glucose +ve
-oxidase positive
Penicillin, cefotaxime (chloramphenicol)
-followed by eradicative treatment: rifampicin or ciprofloxacin often accompanied by corticosteroids
Vaccines available for group A, C, Y and W135; - tetravalent conjugate given since 2015
Introduction of 4CMenB vaccine (Bexsero) in 2015 for infants and at-risk groups.
But expensive – I.e. for non-developed countries, and even in UK MenB was a tricky sell to UK-JCVI
Haemophilus influenzae G -ve cocco-bacillus
Originally isolated from influenza sufferers (1892 Pfeiffer), thus H. influenzae
Thought to be causative agent of flu until 1933!
Non-invasive disease : otitis media, sinusitis
(2 - 4 yrs old)
Causes septicaemia, pneumonia and meningitis
-meningitis and pneumonia (4 months - 2 years old)
-invasion – penetration of submucosa of nasopharynx
-complications: epiglottitis, bacteraemia, cellulitis
-15 -35 % survivors with disability